Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 1;5(3):804-26.
doi: 10.1177/193229681100500336.

Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system)

David C Klonoff  1 , Charles L Zimliki, Lcdr Alan Stevens, Patricia Beaston, Arleen Pinkos, Sally Y Choe, Guillermo Arreaza-Rubín, William Heetderks
Affiliations

Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system)

David C Klonoff et al. J Diabetes Sci Technol. .

Abstract

The Food and Drug Administration in collaboration with the National Institutes of Health presented a public workshop to facilitate medical device innovation in the development of the artificial pancreas (or autonomous system) for the treatment of diabetes mellitus on November 10, 2010 in Gaithersburg, Maryland. The purpose of the workshop was to discuss four aspects of artificial pancreas research and development, including: (1) the current state of device systems for autonomous systems for the treatment of diabetes mellitus; (2) challenges in developing this expert device system using existing technology; (3) clinical expectations for these systems; and (4) development plans for the transition of this device system toward an outpatient setting. The patients discussed how clinical science, system components, and regulatory policies will all need to harmonize in order to achieve the goal of seeing an AP product brought forward to the marketplace for patients to use.

PubMed Disclaimer

References

    1. Pickup JC, Viberti GC, Bilous RW, Keen H, Alberti KG, Home PD, Binder C. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia. 1982;22(3):175–179. - PubMed
    1. Scheen A, Castillo M, Jandrain B, Krzentowski G, Henrivaux P, Luyckx AS, Lefèbvre PJ. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Diabetes Care. 1984;7(4):338–342. - PubMed
    1. Castillo MJ, Scheen AJ, Lefèbvre PJ. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose level. J Clin Endocrinol Metab. 1996;81(5):1975–1978. - PubMed
    1. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16(2):244–248. - PubMed
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care. 2010;33(5):1004–1008. - PMC - PubMed

Publication types